Last reviewed · How we verify
infections that are proven or strongly suspected to be caused by susceptible bacteria — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Xerava | ERAVACYCLINE | Tetraphase Pharms | 2019-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Tetraphase Pharms · 1 drug in infections that are proven or strongly suspected to be caused by susceptible bacteria
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in infections that are proven or strongly suspected to be caused by susceptible bacteria:
- infections that are proven or strongly suspected to be caused by susceptible bacteria treatment updates — RSS
- infections that are proven or strongly suspected to be caused by susceptible bacteria treatment updates — Atom
- infections that are proven or strongly suspected to be caused by susceptible bacteria treatment updates — JSON
Cite this brief
Drug Landscape (2026). infections that are proven or strongly suspected to be caused by susceptible bacteria — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/infections-that-are-proven-or-strongly-suspected-to-be-caused-by-susceptible-bacteria. Accessed 2026-06-10.
Related
- infections that are proven or strongly suspected to be caused by susceptible bacteria full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing